Effect of Memantine on Cognitive Impairment in Patients With Epilepsy
Słowa kluczowe
Abstrakcyjny
Opis
Epilepsy is a complex disorder, which involves much more than seizures, encompassing a range of associated comorbid health conditions that can have significant health and quality-of-life implications. Of these comorbidities, cognitive impairment is one of the most common and distressing aspects of epilepsy.
Excito-toxicity, mediated by glutamate acting on N-methyl-D-aspartate (NMDA) receptors in the hippocampus, can cause memory dysfunction in epilepsy .
Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor . It also has antioxidant property and increases production of brain derived neurotropic factor (BDNF)
Daktyle
| Ostatnia weryfikacja: | 05/31/2020 |
| Pierwsze przesłane: | 06/01/2020 |
| Szacowana liczba przesłanych rejestracji: | 06/02/2020 |
| Wysłany pierwszy: | 06/03/2020 |
| Ostatnia aktualizacja przesłana: | 06/02/2020 |
| Ostatnia opublikowana aktualizacja: | 06/03/2020 |
| Rzeczywista data rozpoczęcia badania: | 09/30/2018 |
| Szacowana data zakończenia podstawowej działalności: | 09/30/2019 |
| Szacowana data zakończenia badania: | 01/14/2020 |
Stan lub choroba
Interwencja / leczenie
Drug: Memantine hydrochloride group
Drug: Placebo group
Faza
Grupy ramion
| Ramię | Interwencja / leczenie |
|---|---|
| Active Comparator: Memantine hydrochloride group included 50 patients who received memantine | Drug: Memantine hydrochloride group Memantine is a low-affinity voltage-dependent uncompetitive antagonist of the NMDA-type glutamate receptor .Memantine hydrochloride tablet was started at the dose of 5 mg once daily orally, and the same dose was given for 3months and dose is titrated to 10 mg once daily orally for the remaining 3months. Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day. |
| Placebo Comparator: Placebo group included 50 patients who received placebo | Drug: Placebo group Placebo was given once daily orally for6months. Patients were instructed to take the study medication at the same time every day. |
Kryteria kwalifikacji
| Wiek kwalifikujący się do nauki | 18 Years Do 18 Years |
| Płeć kwalifikująca się do nauki | All |
| Przyjmuje zdrowych wolontariuszy | tak |
| Kryteria | Inclusion Criteria: - Patients with idiopathic epilepsy. - Normal brain imaging (CT brain). - Patients on anti epileptic drugs more than 6 months. - No more than two fits per month. - Score of Mini mental state examination (10-24), mild and moderate cognitive impairment. - No other medical disorders. Exclusion Criteria: - Progressive neurological diseases. - Abnormal brain imaging (CT brain). - More than two fits per month. - Patients with severe cognitive impairment, score of MMSE less than10. - Patients with severe medical disorders |
Wynik
Podstawowe miary wyników
1. Memory Assessment Scale (MAS) [1.5years]
2. Wechsler Adult Intelligence Scale (WAIS) [1.5years]
3. Brief Visuospatial Memory Test-Revised (BVMT-R) [1.5years]
